JP2010529999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529999A5 JP2010529999A5 JP2010512385A JP2010512385A JP2010529999A5 JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5 JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polysorbate
- phosphate buffer
- sodium chloride
- sodium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94407607P | 2007-06-14 | 2007-06-14 | |
| PCT/US2008/066928 WO2008157356A2 (en) | 2007-06-14 | 2008-06-13 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182749A Division JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529999A JP2010529999A (ja) | 2010-09-02 |
| JP2010529999A5 true JP2010529999A5 (cg-RX-API-DMAC7.html) | 2011-07-28 |
Family
ID=39956053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512385A Pending JP2010529999A (ja) | 2007-06-14 | 2008-06-13 | 抗体製剤 |
| JP2013182749A Pending JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013182749A Pending JP2014040424A (ja) | 2007-06-14 | 2013-09-04 | 抗体製剤 |
Country Status (24)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| US20120183531A1 (en) * | 2009-07-14 | 2012-07-19 | Biogen Idee Ma Inc | Methods for Inhibiting Yellow Color Formation in a Composition |
| EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| HUE047173T2 (hu) | 2010-03-01 | 2020-04-28 | Bayer Healthcare Llc | Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen |
| MX340683B (es) | 2010-04-16 | 2016-07-21 | Biogen Ma Inc | Anticuerpos anti-vla-4. |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| WO2013006461A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Cholesterol-based media supplementals for cell culture |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CN104010654B (zh) * | 2011-10-18 | 2017-10-27 | 科荣生生物科学公司 | 金属离子稳定的依那西普制剂 |
| ES2732243T3 (es) * | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| SG11201407779YA (en) * | 2012-06-21 | 2015-02-27 | Ucb Pharma Sa | Pharmaceutical formulation |
| HK1209343A1 (en) | 2012-07-09 | 2016-04-01 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| HRP20180182T1 (hr) | 2012-09-11 | 2018-04-20 | Coherus Biosciences, Inc. | Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa |
| CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
| EP3062814A1 (en) * | 2013-10-29 | 2016-09-07 | Albumedix A/S | Antibody composition |
| BR112016009862B1 (pt) * | 2013-11-29 | 2021-12-21 | Genentech, Inc | Método de fabricação de uma composição |
| JP2017514458A (ja) | 2014-03-12 | 2017-06-08 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ４−５に対して特異的な抗−ラミニン４抗体 |
| KR20170052526A (ko) * | 2014-03-13 | 2017-05-12 | 프로테나 바이오사이언시즈 리미티드 | 다발성 경화증에 대한 병용 치료 |
| AR100716A1 (es) * | 2014-06-02 | 2016-10-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Producción de fragmentos fc |
| WO2016059512A1 (en) * | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
| RU2018141451A (ru) | 2016-05-27 | 2020-06-29 | Алексион Фармасьютикалс, Инк. | Способы лечения рефрактерной генерализованной миастении |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| MX2020004284A (es) | 2017-10-26 | 2020-10-28 | Alexion Pharma Inc | Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua). |
| WO2019198101A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy’S Laboratories Limited | Stable formulations of therapeutic antibody |
| KR102848349B1 (ko) | 2018-06-04 | 2025-08-21 | 바이오젠 엠에이 인코포레이티드 | 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체 |
| WO2020006266A1 (en) * | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| KR20220034169A (ko) * | 2019-07-10 | 2022-03-17 | 리제너론 파아마슈티컬스, 인크. | 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물 |
| AU2020337093B2 (en) * | 2019-08-30 | 2025-02-27 | Kashiv Biosciences, Llc | Novel formulation of highly concentrated pharmacologically active antibody |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| JPWO2022092183A1 (cg-RX-API-DMAC7.html) * | 2020-10-30 | 2022-05-05 | ||
| MX2023005596A (es) | 2020-11-14 | 2023-08-15 | Biogen Ma Inc | Regímenes de dosificación bifásica subcutánea para anticuerpos anti-vla-4. |
| WO2022221458A1 (en) | 2021-04-13 | 2022-10-20 | Biogen Ma Inc | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JPS62196921A (ja) | 1986-02-25 | 1987-08-31 | Nec Corp | 位相検出回路 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| PL174772B1 (pl) | 1993-01-06 | 1998-09-30 | Kinerton Ltd | Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy |
| SG44845A1 (en) * | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| NZ279730A (en) * | 1994-01-25 | 1998-04-27 | Athena Neurosciences Inc | Humanized antibodies against leukocyte adhesion molecule vla-4 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| BRPI9707379B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| MXPA02007291A (es) | 2000-01-27 | 2002-11-29 | American Cyanamid Co | Metodo para preparar derivados de acido alfa-sulfonil hidroxamico. |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DK2236154T3 (en) * | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| WO2006055871A2 (en) * | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
| WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
-
2008
- 2008-06-13 JP JP2010512385A patent/JP2010529999A/ja active Pending
- 2008-06-13 NZ NZ582436A patent/NZ582436A/en unknown
- 2008-06-13 HU HUE08771026A patent/HUE041555T2/hu unknown
- 2008-06-13 CN CN201410163087.4A patent/CN103977404A/zh active Pending
- 2008-06-13 EA EA201070015A patent/EA020456B1/ru unknown
- 2008-06-13 WO PCT/US2008/066928 patent/WO2008157356A2/en not_active Ceased
- 2008-06-13 ES ES08771026T patent/ES2707815T3/es active Active
- 2008-06-13 EP EP08771026.5A patent/EP2170390B1/en active Active
- 2008-06-13 PL PL08771026T patent/PL2170390T3/pl unknown
- 2008-06-13 BR BRPI0814252A patent/BRPI0814252B8/pt active IP Right Grant
- 2008-06-13 LT LTEP08771026.5T patent/LT2170390T/lt unknown
- 2008-06-13 SI SI200832029T patent/SI2170390T1/sl unknown
- 2008-06-13 TR TR2018/20837T patent/TR201820837T4/tr unknown
- 2008-06-13 EP EP18193307.8A patent/EP3461500A1/en active Pending
- 2008-06-13 DK DK08771026.5T patent/DK2170390T3/en active
- 2008-06-13 AU AU2008266051A patent/AU2008266051B2/en active Active
- 2008-06-13 NZ NZ595526A patent/NZ595526A/xx unknown
- 2008-06-13 US US12/139,362 patent/US20080311119A1/en not_active Abandoned
- 2008-06-13 CN CN200880102434A patent/CN101778640A/zh active Pending
- 2008-06-13 HR HRP20182146TT patent/HRP20182146T1/hr unknown
- 2008-06-13 AR ARP080102545A patent/AR067011A1/es not_active Application Discontinuation
- 2008-06-13 MX MX2009013593A patent/MX2009013593A/es active IP Right Grant
- 2008-06-13 PT PT08771026T patent/PT2170390T/pt unknown
- 2008-06-13 TW TW097122335A patent/TWI614028B/zh active
- 2008-06-13 CA CA2690382A patent/CA2690382A1/en not_active Abandoned
-
2009
- 2009-12-10 IL IL202648A patent/IL202648B/en active IP Right Grant
- 2009-12-11 MX MX2020005214A patent/MX2020005214A/es unknown
-
2012
- 2012-01-27 US US13/359,959 patent/US20120134989A1/en not_active Abandoned
- 2012-06-22 US US13/530,879 patent/US9533044B2/en active Active
-
2013
- 2013-09-04 JP JP2013182749A patent/JP2014040424A/ja active Pending
-
2019
- 2019-02-01 CY CY20191100146T patent/CY1121208T1/el unknown
- 2019-03-19 AR ARP190100691A patent/AR117403A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529999A5 (cg-RX-API-DMAC7.html) | ||
| JP2010522208A5 (cg-RX-API-DMAC7.html) | ||
| JP2011088913A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513069A5 (cg-RX-API-DMAC7.html) | ||
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| UA107557C2 (xx) | Композиція антитіла офатумумабу | |
| PL2315580T3 (pl) | Formulacje farmaceutyczne oraz sposoby leczenia infekcji dróg oddechowych | |
| JP2012184234A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161577T1 (hr) | Inhibitori replikacije virusa gripe | |
| UA115648C2 (uk) | Доставка терапевтичних агентів до цнс | |
| JP2015527402A5 (cg-RX-API-DMAC7.html) | ||
| HRP20110414T1 (hr) | Indoli i njihova uporaba u liječenju | |
| CL2012001966A1 (es) | Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis. | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| HRP20150744T4 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| MY166045A (en) | Abeta antibody formulation | |
| RU2009126767A (ru) | Производное 1-фенил-1-тио-d-глюцитола | |
| NO20082904L (no) | Feksofenadinsupensjonsformulering | |
| EP1885380A4 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ARSENE (III ACID), SODIUM SALT AND THEIR DERIVATIVES FOR THE TREATMENT OF UROGENITAL CANCER AND METASTASES THEREOF | |
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| JP2005527551A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510747A5 (cg-RX-API-DMAC7.html) | ||
| TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno |